These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8174824)

  • 1. Decisions on screening for viral markers in blood donors.
    Zuck TF
    Dev Biol Stand; 1993; 81():91-100. PubMed ID: 8174824
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined testing for viral markers.
    Barbara J
    Dev Biol Stand; 1993; 81():87-9. PubMed ID: 8174823
    [No Abstract]   [Full Text] [Related]  

  • 3. [Frequency of HIV positivity in donors. Follow-up of ambiguous Western blots].
    Padrón F; Ortiz de Lejarazu R; Eirós JM; Ortiz V
    Sangre (Barc); 1991 Oct; 36(5):436-8. PubMed ID: 1816645
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of prevalence rates of microbiological markers between bone/tissue donations and new blood donors in Scotland.
    Galea G; Dow BC
    Vox Sang; 2006 Jul; 91(1):28-33. PubMed ID: 16756598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Viral safety considerations in immunoglobulin preparations].
    Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
    Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
    [No Abstract]   [Full Text] [Related]  

  • 6. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
    Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
    Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current value of serologic test for syphilis as a surrogate marker for blood-borne viral infections among blood donors in the United States.
    Zou S; Notari EP; Fang CT; Stramer SL; Dodd RY
    Transfusion; 2009 Apr; 49(4):655-61. PubMed ID: 19170999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C seroprevalence in accepted versus deferred blood-donor candidates evaluated by medical history and self-exclusion form.
    López RA; Romero-Estrella S; Infante-Ramírez L; Méndez-Aquino JS; Berrón-Ruiz P; Morales-Alfaro NA; Vivar R; Carrada E; Rivera-Rendón Mdel R; Sánchez-Guerrero SA
    Transfusion; 2004 Sep; 44(9):1344-9. PubMed ID: 15318859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The improvement of a serological screening method in blood transfusion].
    Cernescu C; Cristea A; Deutsch I
    Rev Roum Virol; 1990; 41(3-4):181-95. PubMed ID: 2099829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of selected viral infections among blood donors deferred for potential risk to blood safety.
    Zou S; Fujii K; Johnson S; Spencer B; Washington N; Iv EN; Musavi F; Newman B; Cable R; Rios J; Hillyer KL; Hillyer CD; Dodd RY;
    Transfusion; 2006 Nov; 46(11):1997-2003. PubMed ID: 17076856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIDS: blood donor studies and screening programs.
    Kaplan HS; Kleinman SH
    Prog Clin Biol Res; 1985; 182():297-308. PubMed ID: 3875866
    [No Abstract]   [Full Text] [Related]  

  • 12. [HIV and other retroviruses in the screening of blood donors].
    Bonanni G; D'Ambrosio F; Marino S
    Recenti Prog Med; 1991 Feb; 82(2):122-4. PubMed ID: 2034869
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetic diversity of viruses. Consequences for screening and prevention].
    Barin F; Laperche S; Couroucé AM
    Transfus Clin Biol; 2000 Oct; 7(5):472-8. PubMed ID: 11109632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Topicality of serologic screening of human immunodeficiency virus infections in adults].
    Dubrous P; Koeck JL; Coulot P; Blanchard de Vaucouleurs A
    Pathol Biol (Paris); 1998 Jan; 46(1):61-6. PubMed ID: 9769938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Deontology, ethics, and AIDS].
    Daher M; Mokhbat J; Tohmé S
    J Med Liban; 1993; 41(2):109-11. PubMed ID: 8057342
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of selected viral infections among temporarily deferred donors who returned to donate blood: American Red Cross blood donor study.
    Zou S; Musavi F; Notari EP; Fujii KE; Dodd RY;
    Transfusion; 2005 Oct; 45(10):1593-600. PubMed ID: 16181210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of seropositivity and problems linked to the identification of seropositive persons].
    Fara GM; Guasticchi G
    Nuovi Ann Ig Microbiol; 1988; 39(4-5):343-5. PubMed ID: 3254488
    [No Abstract]   [Full Text] [Related]  

  • 20. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Japan.
    Yugi H; Hino S; Satake M; Tadodoro K
    Vox Sang; 2005 Nov; 89(4):265. PubMed ID: 16262762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.